---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-011202"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:20:09.148910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q3 net loss $5.79M ($0.37/sh); Phase 3 ARDS study expanded; Phase 2b on track

## Summary
- Net loss for Q3 fiscal 2022: $5.79M ($0.37/sh) vs $4.76M ($0.36/sh) in prior year; nine-month loss $14.74M ($1.04/sh).
- Phase 3 ARDS study for Covid-19 expanded to second cohort; parallel recruitment underway.
- Phase 2b ACD study expects to randomize all 210 subjects by Q4 2022 with topline data in early 2023.
- Cash and equivalents $12.81M; working capital $9.52M at June 30, 2022.
- Operating expenses for Q3 were $5.80M, down from $6.07M YoY, driven by lower G&A and share-based compensation.

## SEC filing metadata
- accession: 0001654954-22-011202
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/0001654954-22-011202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495422011202/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-011202
- JSON: https://secwatch.observer/filing/0001654954-22-011202.json
- Plain text: https://secwatch.observer/filing/0001654954-22-011202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.